title: Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.
abstract: The efficacy of antifolate, antiviral, and other drugs was compared in an experimental model of pneumocystosis. Sulfamethoxazole (SMX) administered alone in doses of greater than or equal to 60 mg/kg/day was highly effective in treatment and prophylaxis. Low (less than or equal to 15 mg/kg/day) doses of SMX showed limited, dose-related anti-Pneumocystis carinii activity in therapy but were more effective in prophylaxis. The dihydrofolate reductase (DHFR) inhibitors trimethoprim (TMP), pyrimethamine, and trimetrexate exhibited little anti-P. carinii activity when administered alone and did not enhance the efficacy of SMX; the effects of the DHFR inhibitors could not be related to the dose or the concentration in serum. These data suggested that the rat model is an excellent system for studying the anti-P. carinii activity of sulfonamides but is of limited value in studying DHFR inhibitors. The antiviral drugs azidothymidine, dideoxyinosine, inosine pranobex (Isoprinosine), amantadine, and acyclovir displayed little or no activity against P. carinii; however, azidothymidine did not impair the efficacy of SMX or TMP-SMX. These results supported the clinical practice of giving antiviral agents together with antifolate drugs to patients infected with human immunodeficiency virus and suggested that the beneficial effects of antiviral agents on the occurrence of pneumocystosis are due mainly to their effects on the virus or the host immune response. In contrast to the antiviral drugs, 9-deazainosine, a nucleoside analog with antiprotozoal properties, demonstrated marked activity against P. carinii which was related to dose and route of administration. These data raised the possibility that anti-P. carinii activity is a general property of purine nucleosides and suggested that further exploration of this class of compounds might lead to clinically useful agents.
authors.affiliation: Cincinnati Veterans Affairs Medical Center, Ohio.
authors.forename: P D
authors.initials: PD
authors.lastname: Walzer
authors.forename: J
authors.initials: J
authors.lastname: Foy
authors.forename: P
authors.initials: P
authors.lastname: Steele
authors.forename: C K
authors.initials: CK
authors.lastname: Kim
authors.forename: M
authors.initials: M
authors.lastname: White
authors.forename: R S
authors.initials: RS
authors.lastname: Klein
authors.forename: B A
authors.initials: BA
authors.lastname: Otter
authors.forename: C
authors.initials: C
authors.lastname: Allegra
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D005493:Folic Acid Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013420:Sulfamethoxazole / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D005493:Folic Acid Antagonists; D015215:Zidovudine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013420:Sulfamethoxazole